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Abstract
New 2016 ACR/EULAR classification criteria for primary Sjogren’s syndrome (SS) have been developed and endorsed
by the ACR. The newly proposed criteria include simple-to-perform items.
Two important points of the new criteria should be considered. Firstly, they indicate that either salivary gland
biopsy or anti-Ro must be positive in order to corroborate the inflammatory and autoimmune nature of the
disease. Secondly, the criteria recognize the systemic nature of SS, namely that patients without salivary or ocular
glandular symptoms, but with extraglandular manifestations and B cell activation markers were also included in the
SS classification. Additionally, the new criteria modified some technical points. The ocular staining score threshold
was increased to 5 due to the higher specificity. The immunological profile includes only anti-Ro antibodies, while
positivity for antinuclear antibodies and rheumatoid factor or isolated anti-La was excluded due to a lack of
specificity.
The 2016 ACR/EULAR criteria are suitable for early identification of SS, providing patients with the opportunity of
enrollment in clinical trials for new specific treatment. Although validation has been successful, the real life
application of these criteria will test their performance.
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Background
Sjögren’s syndrome (SS) is a systemic disease with
inflammatory chronic involvement of exocrine glands,
mainly ocular and salivary glands. Other organs may be
involved in more than 30% of cases and, occasionally,
extra-glandular manifestations can occur early during
the course of the disease [1, 2]. Although disease patho-
genesis has not yet been fully elucidated, substantial data
has demonstrated that SS is an autoimmune disease,
with autoantibodies to Ro and La acting as its immuno-
logical markers [3].
Since 1965, a number of classification criteria sets for SS
have been proposed by single experts or groups of multi-
disciplinary specialists [4–10]. Over the past 15 years, two
sets of criteria have been published. The first was
proposed by the American-European Consensus Group
(AECG) in 2002, and has been extensively used for
research and clinical purposes [10]. The second, more
recent set was published by the Sjögren’s International
Collaborative Clinical Alliance (SICCA), funded by the
National Institutes of Health and provisionally en-
dorsed by the American College of Rheumatology
(ACR), with the aim to classify patients for enrollment
in clinical trials [11]. A comparison between AECG and
ACR criteria, performed in 2014, found an excellent
concordance rate of 0.81, but also clearly showed that
some items, especially for ocular involvement, needed
further revision [12]. Thus, the existence of two
scientifically validated, similarly performing set of
criteria, despite their major differences, led the
scientific community to recognize the need for an
international consensus on classification criteria. Under
the umbrella of the European League against Rheumatism
(EULAR) and ACR, investigators from the AECG and
SICCA groups collaborated to develop the 2016 ACR/
EULAR classification criteria for primary SS [13].* Correspondence: ilariacava@virgilio.it1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia,
Italy
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Discussion
Was there really a need for a new set of criteria for SS?
AECG criteria comprise a number of positive features,
including their simple application and the stepwise
approach to patient classification in a rheumatologist’s
office without the need for invasive tests provided that
ocular and salivary subjective items along with
Schirmer’s test and anti-Ro are satisfied. Similarly,
SICCA criteria are also simple, but rely only on objective
tests, two of which (ocular staining score and lip biopsy)
are invasive and cannot be performed in an outpatient
setting. Nevertheless, they do not consider radiological
and scintigraphic gland examination, which are presently
rarely used for diagnostic purposes. A limitation in both
sets of criteria was the lack of early detection of SS.
However, there was sufficient data to justify the amal-
gamation of the two sets of criteria into a single consen-
sus formulation. Therefore, the 2016 ACR/EULAR
criteria were formulated to combine features from both
the SICCA and AECG criteria.
The methodology used in the development of the 2016
ACR/EULAR criteria for SS mirrored that used for the
successful development and validation of the ACR/
EULAR criteria for rheumatoid arthritis [14] and
systemic sclerosis [15], providing a simple scoring sys-
tem applicable in daily routine clinical practice. Unfortu-
nately, in the absence of an objective “gold standard” to
define the disease, the clinician-expert opinion and
consensus still represent the best instruments to build a
criteria set, as indeed expressed by the authors [13].
Innovative features of the new classification criteria
The newly proposed criteria include only objective and
rather simple-to-perform items. In addition, they are
based on a weighted sum of items easily applied in real-
life clinical settings.
Objective ocular and oral symptoms have been
excluded; nevertheless, they continue to be considered
important in evoking the clinical suspicion of SS and
guiding the performance of clinical tests.
In this scenario, two other important findings were
considered. Primarily, as in AECG criteria, either one of
salivary gland biopsy and anti-Ro must be positive in
order to emphasize the inflammatory and autoimmune
nature of the disease. Secondly, the systemic nature of
SS was recognized, allowing the classification of SS for
patients even without salivary and ocular symptoms, but
with extraglandular manifestations and B cell activation
markers. It is well known that, not infrequently, SS is di-
agnosed after the onset of interstitial nephritis [16] or
neurological involvement [17]. Furthermore, these classi-
fication criteria could lead to earlier recognition of a
patient having SS, because systemic symptoms and/or B
cell activation markers are frequently occurring in young
patients, with no or scanty symptoms of sicca. Given the
purpose of the 2016 criteria of also identifying patients
for clinical trials, these young SS patients could particu-
larly benefit from the new therapeutic options.
The new criteria also modified certain technical issues.
The ocular staining score threshold was increased to 5
due to the higher specificity [12], compared to the previ-
ous score of 3 [11]. The immunological profile includes
only anti-Ro antibodies, while positivity for antinuclear
antibodies and rheumatoid factor or for isolated anti-La
was excluded. Antinuclear antibodies and rheumatoid
factor positivity had been included as SS criteria in many
previous classification sets [7, 8, 11], but were consid-
ered too unspecific to be confirmed in the new criteria.
The exclusion of isolated anti-La was based on reliable
data showing that anti-Ro antibodies are usually
detected either solely or concomitantly with anti-La,
whereas anti-La antibodies only seldom exist in isolation
[18]. The use of highly sensitive multiparametric assays
frequently leads to the detection of isolated anti-La anti-
bodies, with consequent difficulties in results interpret-
ation. The Ro/La system is considered a heterogeneous
antigenic complex, constituted by small RNA particles
and three proteins (namely Ro52, Ro60 and La), bound
together, with peculiar antigenic properties [3]. The vari-
ous assays do not perform equally in anti-Ro and anti-La
detection, depending on the antigenic source [3]. How-
ever, there is no mention in any of the classification
criteria for SS of the laboratory methods for autoanti-
body determination; nevertheless, particular care should
be considered for anti-Ro detection since the majority of
anti-Ro antibodies target conformational epitopes. All
assays, whether automated or manual, should include
conformational Ro antigens to obtain accurate results.
Anti-Ro antibodies represent a crucial item for the diag-
nosis of SS – the occurrence of both anti-Ro60 and anti-
Ro52 antibodies, years prior to diagnosis, has been
recently demonstrated to show the highest positive
predictive value for future development of SS, especially
in younger subjects [19].
Future directions and conclusions
The new criteria are open for future modifications such
as the introduction of anti-Ro profile or parotid ultra-
sonography. However, the hypothesis to improve
serological determination to distinguish between mono-
specific antibody assays of Ro60 and Ro52 antibodies
does not seem particularly useful considering that
isolated anti-Ro52 antibodies are frequently found in
different autoimmune diseases and are not specific to
SS [20].
With the omission of scialography and salivary scintig-
raphy, which were included in AECG criteria [8, 10], the
oral component of the disease is now assessed by labial
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salivary gland biopsy and whole unstimulated salivary
flow. No other radiological investigation was considered
useful. Nevertheless, if precise guidelines allowing the
standardization and eradication of inter-observer
variability of salivary gland ultrasonography become
available, then this technique could be considered for
inclusion in the criteria. Indeed, the high accessibility,
low cost, and non-invasiveness make ultrasonography an
important tool for salivary gland assessment in patients
with SS [21].
The strength of the 2016 ACR/EULAR criteria lies in
their appropriateness for early identification of SS,
providing patients with the opportunity to be enrolled in
clinical trials for new disease-modifying drugs for SS.
Although the exercise of validation has been successful,
the real life application of these criteria will test their
performance.
Abbreviations
ACR: American college of rheumatology; ECG: American-european consensus
group; EULAR: European league against rheumatism; SICCA: Sjögren’s
international collaborative clinical alliance; SS: Sjögren’s syndrome
Authors’ contributions
All the authors analyzed and discussed recent publications on the subject. FF
and IC equally contributed to the writing of this manuscript. L A and AT
performed the editing of the text. All the authors discussed and approved
the final manuscript.
Authors’ information
AT is a physician and Full Professor of Rheumatology at the University of
Brescia and Head of Rheumatology and Clinical Immunology Unit of Spedali
Civili of Brescia. LA is a physician and Assistant Professor at the same
University and Hospital. FF and IC are both physicians working at the
Rheumatology and Clinical Immunology Unit at Spedali Civili of Brescia. All
authors are involved in daily clinical work and research studies on systemic
autoimmune diseases, including Sjogren’s syndrome.
Competing interests





Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia,
Italy. 2Clinical and Experimental Science Department, University of Brescia,
Brescia, Italy.
Received: 2 March 2017 Accepted: 15 March 2017
References
1. Tincani A, Andreoli L, Cavazzana I, et al. Novel aspects Sjogren’s syndrome
in 2012. BMC Med. 2013;11:93.
2. Ramos-Casals M, Brito-Zeron P, Solans R, et al. Systemic involvement in
primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity
index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology
(Oxford). 2014;53:321–31.
3. Franceschini F, Cavazzana I. Anti-Ro/SSA and anti-La/SSB antibodies.
Autoimmunity. 2005;38:55–63.
4. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjogren’s syndrome: a clinical,
pathological, and serological study of sixty-two cases. Medicine (Baltimore).
1965;44:187–231.
5. Daniels TE, Silverman Jr S, Michalski JP, Greenspan JS, Sylvester RA, Talal N.
The oral component of Sjogren’s syndrome. Oral Surg Oral Med Oral Pathol.
1975;39:875–85.
6. Skopouli FN, Drosos AA, Papaioannou T, Moutsopoulos HM. Preliminary
diagnostic criteria for Sjogren’s syndrome. Scand J Rheumatol Suppl.
1986;61:22–5.
7. Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjogren’s syndrome:
proposed criteria for classification. Arthritis Rheum. 1986;29:577–85.
8. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W,
Bernstein RM, et al. Preliminary criteria for the classification of Sjogren’s
syndrome: results of a prospective concerted action supported by the
European Community. Arthritis Rheum. 1993;36:340–7.
9. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese
criteria for Sjogren’s syndrome (1999): availability and validity. Mod
Rheumatol. 2004;14:425–34.
10. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons
SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of
the European criteria proposed by the American-European Consensus
Group. Ann Rheum Dis. 2002;61:554–8.
11. Shiboski SC, Shiboski CH, Criswell LA, et al. American College of
Rheumatology classification criteria for Sjogren’s syndrome: a data-driven
expert consensus approach in the Sjogren’s International Collaborative
Clinical Alliance Cohort. Arthritis Care Res. 2012;64:475–87.
12. Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European
Consensus Group Sjogren's syndrome classification criteria to newly
proposed American College of Rheumatology criteria in a large, carefully
characterised sicca cohort. Ann Rheum Dis. 2014;73:31–8.
13. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of
Rheumatology/European League Against Rheumatism classification criteria
for primary Sjögren’s syndrome: a consensus and data-driven methodology
involving three international patient cohorts. Ann Rheum Dis. 2017;76:9–16.
14. Aletah D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification
criteria: an American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8.
15. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for
systemic sclerosis: an American College of Rheumatology/European League
Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737–47.
16. Bossini N, Savoldi S, Franceschini F, et al. Clinical and morphological
features of kidney involvement in primary Sjögren’s syndrome. Nephrol Dial
Transplant. 2001;16:2328–36.
17. Jamilloux Y, Magy L, Hurtevent JF, et al. Immunological profiles determine
neurological involvement in Sjögren’s syndrome. Eur J Intern Med.
2014;25:177–81.
18. Routsias JG, Tzioufas AG. Sjögren’s syndrome–study of autoantigens and
autoantibodies. Clin Rev Allergy Immunol. 2007;32:238–51.
19. Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G.
Prediction of Sjögren's syndrome years before diagnosis and identification
of patients with early onset and severe disease course by autoantibody
profiling. Arthritis Rheum. 2015;67:2427–36.
20. Shulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A
autoantibody system. Autoimmun Rev. 2009;8:632–7.
21. Cornec D, Jousse-Joulin S, Pers J-O, Marhadour T, Cochener B, Boisrame-
Gastrin S, Nowak E, Youinou P, Saraux A, Devauchelle-Pensec V.
Contribution of salivary gland ultrasonography to the diagnosis of Sjogren’s
syndrome toward new diagnostic criteria? Arthritis Rheum. 2013;65:216–25.
Franceschini et al. BMC Medicine  (2017) 15:69 Page 3 of 3
